Jardine Matheson’s $2.4 Billion I-MED Deal Marks a Serious Push Into Healthcare Diagnostics

Jardine Matheson’s acquisition of I-MED is more than a healthcare bolt-on; it is a signal that the nearly two-century-old conglomerate wants to reshape its portfolio toward businesses with durable demand, stronger growth profiles, and clearer control ownership. Jardine has historically been associated with property, retail, hotels, automotive, and consumer-facing businesses across Asia. By buying 100% of I-MED from Permira-advised funds and other shareholders, the group is moving deeper into healthcare diagnostics, a sector supported by aging populations, rising scan volumes, and the increasing use of imaging in preventive and specialist care.

The price is not cheap. Reuters reported that the deal values I-MED at around 11.5 times forecast adjusted EBITDA for the year ending June 2026, excluding the Harrison.ai stake. Reuters Breakingviews noted that I-MED’s EBITDA margin is around 17%, lower than the roughly 20% margin seen in the Integral Diagnostics-Capitol Health deal, meaning Jardine is paying a full price for the asset rather than picking it up opportunistically. That is the risk: Jardine has limited room for easy cost synergies because it does not already own a comparable radiology platform in Australia.

Still, the strategic logic is clear. I-MED is a market leader with scale, clinical infrastructure, and recurring patient demand. It operates 215 diagnostic imaging clinics across Australia and New Zealand, performs more than 7 million procedures annually, and provides teleradiology services in Australia, New Zealand, and the United States. That makes it a rare combination of healthcare services, specialist medical workflow, and digital reading capability. For Jardine, this is attractive because radiology is not only a service business; it is also becoming an AI-enabled infrastructure layer inside healthcare.

The Harrison.ai stake is especially important. Harrison.ai develops radiology AI solutions, and its inclusion gives Jardine exposure to one of the most practical AI applications in healthcare: helping clinicians interpret scans faster and more accurately. AI in radiology is not some vague futuristic story; it is already being tested in real clinical workflows because imaging volumes are rising faster than the supply of radiologists in many markets. If I-MED can combine clinic scale, teleradiology capacity, and AI tools effectively, it could strengthen productivity while preserving clinical standards.

The deal also tells investors something about Jardine’s new direction under CEO Lincoln Pan, who took the role in December. Reuters Breakingviews described the transaction as Pan’s first major deal and argued that Jardine can be more patient than private equity owners because it is not forced to sell assets within a typical fund cycle. That matters because Permira had owned I-MED for roughly seven years, while Jardine can hold the business longer and support gradual expansion into core and new markets. The main test now is execution: Jardine has paid a premium price, so it needs I-MED to keep growing, protect margins, and turn healthcare diagnostics into a real long-term pillar rather than just an expensive diversification move.